Spero Therapeutics Inc Cash Flow Conversion Efficiency
Spero Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Spero Therapeutics Inc (SPRO) has a cash flow conversion efficiency ratio of -0.141x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.35 Million) by net assets ($59.02 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Spero Therapeutics Inc (2015–2025)
Cash flow conversion efficiency of Spero Therapeutics Inc from 2015 to 2025. This chart illustrates how Spero Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View SPRO stock price and chart for real-time trading data and today's change.
Spero Therapeutics Inc Cash Flow Conversion Ratio Explained
Spero Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Spero Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Spero Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Spero Therapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Oriental Food Industries Hold
KLSE:7107
|
0.047x |
|
Sports Entertainment Group Ltd
AU:SEG
|
0.121x |
|
KUYA SILVER CORP.
F:6MR1
|
-0.023x |
|
Edelteq Holdings Berhad
KLSE:0278
|
0.007x |
|
James Bay Minerals Ltd
AU:JBY
|
N/A |
|
SYLA Technologies Co., Ltd. American Depositary Shares
NASDAQ:SYT
|
-0.038x |
|
Snowman Logistics Limited
NSE:SNOWMAN
|
0.109x |
|
Amiad Water Systems Ltd
TA:AMD
|
-0.025x |
Annual Cash Flow Conversion Efficiency for Spero Therapeutics Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Spero Therapeutics Inc from 2015 to 2025. Review SPRO cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $59.02 Million | $-12.62 Million | -0.214x | +57.92% |
| 2024-12-31 | $46.12 Million | $-23.44 Million | -0.508x | -64.67% |
| 2023-12-31 | $106.89 Million | $-32.99 Million | -0.309x | -203.18% |
| 2022-12-31 | $75.93 Million | $-7.73 Million | -0.102x | +86.03% |
| 2021-12-31 | $88.29 Million | $-64.35 Million | -0.729x | -12.07% |
| 2020-12-31 | $132.04 Million | $-85.87 Million | -0.650x | +3.04% |
| 2019-12-31 | $74.57 Million | $-50.02 Million | -0.671x | -96.11% |
| 2018-12-31 | $115.86 Million | $-39.62 Million | -0.342x | +25.71% |
| 2017-12-31 | $84.96 Million | $-39.11 Million | -0.460x | +89.89% |
| 2016-12-31 | $6.36 Million | $-28.96 Million | -4.553x | -112.18% |
| 2015-12-31 | $-257.00K | $-9.61 Million | 37.385x | -- |
About Spero Therapeutics Inc
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including … Read more